4 results
Investigate the activity and safety of amrubicin alone versus amrubicin incombination with cisplatin versus standard treatment for extensive disease(ED) small-cell lung cancer in the first line setting.
The primary objective is the Objective tumor response rate (RECIST). Secondary objectives are: duration of overall response, time to tumor progression (TTP), progression free survival (PFS), overall survival, toxicity profile, incidence of…
To investigate the therapeutic efficacy and feasibility of hyperbaric oxygen (HBO) in addition to standard wound care in patients with pyoderma gangrenosum wounds.
Primary Objective: Major amputation rate after 12-months of follow-upSecondary Objectives: - Amputation-free survival- Health-related quality of life- Complete wound healing- Pain scores- Need for additional (vascular) interventions- Cost-…